ProtoKinetix, Incorporated (PKTX)
USD 0.01
(-16.79%)
USD 0.01
(-16.79%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 415.47 Thousand USD | -78.22% |
| 2022 | 1.9 Million USD | -18.12% |
| 2021 | 2.32 Million USD | -69.53% |
| 2020 | 7.64 Million USD | 82.1% |
| 2019 | 4.19 Million USD | 245.21% |
| 2018 | 1.21 Million USD | -19.57% |
| 2017 | 1.51 Million USD | -0.83% |
| 2016 | 1.52 Million USD | 21.19% |
| 2015 | 1.25 Million USD | 227.48% |
| 2014 | 384.17 Thousand USD | -9.0% |
| 2013 | 422.17 Thousand USD | 143.87% |
| 2012 | 173.11 Thousand USD | -80.87% |
| 2011 | 904.93 Thousand USD | -34.11% |
| 2010 | 1.37 Million USD | 10.22% |
| 2009 | 1.24 Million USD | -19.65% |
| 2008 | 1.55 Million USD | -42.91% |
| 2007 | 2.71 Million USD | 38.89% |
| 2006 | 1.95 Million USD | -59.38% |
| 2005 | 4.81 Million USD | -10.25% |
| 2004 | 5.36 Million USD | 253.59% |
| 2003 | 1.51 Million USD | 10098.58% |
| 2002 | 14.87 Thousand USD | -12.62% |
| 2001 | 17.02 Thousand USD | 48545.71% |
| 2000 | 35.00 USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 72.05 Thousand USD | -10.72% |
| 2024 Q1 | 80.7 Thousand USD | -17.36% |
| 2023 Q2 | 115.57 Thousand USD | 7.98% |
| 2023 Q1 | 107.03 Thousand USD | -81.66% |
| 2023 FY | 367.22 Thousand USD | -80.75% |
| 2023 Q3 | 80.39 Thousand USD | -30.44% |
| 2023 Q4 | 97.66 Thousand USD | 21.49% |
| 2022 Q1 | 517.59 Thousand USD | 31.32% |
| 2022 Q2 | 442.15 Thousand USD | -14.57% |
| 2022 FY | 1.9 Million USD | -18.12% |
| 2022 Q4 | 583.65 Thousand USD | 57.73% |
| 2022 Q3 | 370.04 Thousand USD | -16.31% |
| 2021 FY | 2.32 Million USD | -69.53% |
| 2021 Q1 | 133.07 Thousand USD | -77.13% |
| 2021 Q2 | 403.73 Thousand USD | 203.39% |
| 2021 Q3 | 1.4 Million USD | 247.26% |
| 2021 Q4 | 394.15 Thousand USD | -71.89% |
| 2020 Q4 | 581.81 Thousand USD | -65.52% |
| 2020 Q3 | 1.68 Million USD | -23.5% |
| 2020 Q2 | 2.2 Million USD | -30.4% |
| 2020 Q1 | 3.16 Million USD | 29.13% |
| 2020 FY | 7.64 Million USD | 82.1% |
| 2019 Q2 | 769.25 Thousand USD | 101.15% |
| 2019 FY | 4.19 Million USD | 245.21% |
| 2019 Q1 | 382.43 Thousand USD | 94.69% |
| 2019 Q3 | 591.83 Thousand USD | -23.06% |
| 2019 Q4 | 2.45 Million USD | 314.7% |
| 2018 Q2 | 342.54 Thousand USD | 12.2% |
| 2018 Q1 | 305.28 Thousand USD | -40.17% |
| 2018 Q3 | 371.77 Thousand USD | 8.53% |
| 2018 Q4 | 196.43 Thousand USD | -47.16% |
| 2018 FY | 1.21 Million USD | -19.57% |
| 2017 Q3 | 299.19 Thousand USD | -8.54% |
| 2017 FY | 1.51 Million USD | -0.83% |
| 2017 Q1 | 375.38 Thousand USD | 0.17% |
| 2017 Q2 | 327.13 Thousand USD | -12.85% |
| 2017 Q4 | 510.26 Thousand USD | 70.55% |
| 2016 Q1 | 344.85 Thousand USD | -27.51% |
| 2016 Q2 | 370.78 Thousand USD | 7.52% |
| 2016 Q3 | 432.07 Thousand USD | 16.53% |
| 2016 Q4 | 374.74 Thousand USD | -13.27% |
| 2016 FY | 1.52 Million USD | 21.19% |
| 2015 Q1 | 257.3 Thousand USD | 38.9% |
| 2015 Q4 | 475.76 Thousand USD | 102.54% |
| 2015 Q3 | 234.9 Thousand USD | -19.04% |
| 2015 Q2 | 290.12 Thousand USD | 12.75% |
| 2015 FY | 1.25 Million USD | 227.48% |
| 2014 Q4 | 185.24 Thousand USD | 191.99% |
| 2014 Q3 | 63.44 Thousand USD | 6.18% |
| 2014 Q2 | 59.74 Thousand USD | -21.12% |
| 2014 Q1 | 75.74 Thousand USD | -52.31% |
| 2014 FY | 384.17 Thousand USD | -9.0% |
| 2013 FY | 422.17 Thousand USD | 143.87% |
| 2013 Q2 | 88.68 Thousand USD | 7.09% |
| 2013 Q4 | 158.81 Thousand USD | 72.88% |
| 2013 Q3 | 91.86 Thousand USD | 3.59% |
| 2013 Q1 | 82.81 Thousand USD | 94.62% |
| 2012 Q2 | 33.48 Thousand USD | -44.53% |
| 2012 Q3 | 38.22 Thousand USD | 14.17% |
| 2012 Q4 | 42.55 Thousand USD | 11.31% |
| 2012 FY | 173.11 Thousand USD | -80.87% |
| 2012 Q1 | 60.35 Thousand USD | -87.97% |
| 2011 Q2 | 186.65 Thousand USD | 60.91% |
| 2011 Q1 | 116 Thousand USD | -70.25% |
| 2011 Q3 | 100.4 Thousand USD | -46.21% |
| 2011 FY | 904.93 Thousand USD | -34.11% |
| 2011 Q4 | 501.87 Thousand USD | 399.85% |
| 2010 Q1 | 167.12 Thousand USD | -75.36% |
| 2010 Q3 | 582.78 Thousand USD | 188.02% |
| 2010 Q4 | 389.93 Thousand USD | -33.09% |
| 2010 FY | 1.37 Million USD | 10.22% |
| 2010 Q2 | 202.33 Thousand USD | 21.07% |
| 2009 Q1 | 122.88 Thousand USD | -26.51% |
| 2009 Q4 | 678.21 Thousand USD | 147.53% |
| 2009 Q3 | 273.98 Thousand USD | 60.21% |
| 2009 FY | 1.24 Million USD | -19.65% |
| 2009 Q2 | 171.02 Thousand USD | 39.17% |
| 2008 FY | 1.55 Million USD | -42.91% |
| 2008 Q3 | 429.51 Thousand USD | -29.51% |
| 2008 Q4 | 167.21 Thousand USD | -61.07% |
| 2008 Q2 | 609.32 Thousand USD | 83.1% |
| 2008 Q1 | 332.77 Thousand USD | -71.36% |
| 2007 Q1 | 286.36 Thousand USD | 291.63% |
| 2007 Q4 | 1.16 Million USD | 15.28% |
| 2007 Q3 | 1 Million USD | 287.3% |
| 2007 Q2 | 260.22 Thousand USD | -9.13% |
| 2007 FY | 2.71 Million USD | 38.89% |
| 2006 Q2 | 1.57 Million USD | 643.21% |
| 2006 Q1 | 212.58 Thousand USD | -76.95% |
| 2006 Q3 | 300.84 Thousand USD | -80.96% |
| 2006 Q4 | -149.44 Thousand USD | -149.67% |
| 2006 FY | 1.95 Million USD | -59.38% |
| 2005 Q3 | 66.52 Thousand USD | -98.12% |
| 2005 Q4 | 922.2 Thousand USD | 1286.19% |
| 2005 FY | 4.81 Million USD | -10.25% |
| 2005 Q2 | 3.53 Million USD | 1152.21% |
| 2005 Q1 | 282.37 Thousand USD | -91.72% |
| 2004 FY | 5.36 Million USD | 253.59% |
| 2004 Q3 | 222.71 Thousand USD | -67.31% |
| 2004 Q2 | 681.3 Thousand USD | -35.29% |
| 2004 Q1 | 1.05 Million USD | -15.56% |
| 2004 Q4 | 3.4 Million USD | 1430.38% |
| 2003 Q4 | 1.24 Million USD | 381.37% |
| 2003 Q3 | 259 Thousand USD | 7493.08% |
| 2003 FY | 1.51 Million USD | 10098.58% |
| 2003 Q2 | 3411.00 USD | 0.0% |
| 2002 FY | 14.87 Thousand USD | -12.62% |
| 2001 FY | 17.02 Thousand USD | 48545.71% |
| 2001 Q3 | - USD | 0.0% |
| 2000 FY | 35.00 USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | 68.888% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 91.76% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 98.594% |
| Nascent Biotech, Inc. | 2.22 Million USD | 81.368% |
| Rebus Holdings, Inc. | 664 Thousand USD | 37.428% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 98.885% |
| Qrons Inc. | 643.67 Thousand USD | 35.452% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -6.652% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 99.277% |
| Skye Bioscience, Inc. | 13.54 Million USD | 96.933% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 99.521% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 91.552% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -58.746% |
| SQZ Biotechnologies Company | 85.61 Million USD | 99.515% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 85.753% |
| Propanc Biopharma, Inc. | 1.5 Million USD | 72.336% |
| Mesoblast Limited | 5.9 Million USD | 92.96% |
| Marizyme, Inc. | 19.23 Million USD | 97.841% |
| Genus plc | 147.7 Million USD | 99.719% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 95.267% |
| Pharming Group N.V. | 225.49 Million USD | 99.816% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | 79.72% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 69.03% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 95.018% |
| ContraFect Corporation | 56.88 Million USD | 99.27% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 90.576% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | 71.903% |
| IMV Inc. | 37.7 Million USD | 98.898% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 85.11% |
| MultiCell Technologies, Inc. | 567.42 USD | -73122.481% |
| ONE Bio Corp. | 6.44 Million USD | 93.552% |
| Accustem Sciences Inc. | 3.74 Million USD | 88.91% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 99.517% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | 21.897% |
| Q BioMed Inc. | 3.43 Million USD | 87.91% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 98.319% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 84.187% |
| Biomind Labs Inc. | 994.18 Thousand USD | 58.209% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 99.582% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | 76.389% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 93.815% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | 77.715% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 1761.916% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 97.405% |
| Curative Biotechnology, Inc. | 1.83 Million USD | 77.359% |
| GB Sciences, Inc. | 1.42 Million USD | 70.751% |
| Alpha Cognition Inc. | 9.7 Million USD | 95.719% |
| HST Global, Inc. | 140.9 Thousand USD | -194.86% |
| CSL Limited | 3.44 Billion USD | 99.988% |
| Wesana Health Holdings Inc. | 1.12 Million USD | 63.066% |
| Halberd Corporation | 74.84 Thousand USD | -455.141% |
| Enzolytics Inc. | 2.17 Million USD | 80.937% |
| Agentix Corp. | 1.37 Million USD | 69.712% |
| Resverlogix Corp. | 12.71 Million USD | 96.732% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 88.619% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.973% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | 60.203% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 82.724% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | 73.693% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 87.798% |
| AVAX Technologies, Inc. | 7.31 Million USD | 94.316% |
| Zenith Capital Corp. | 8.94 Million USD | 95.354% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.95% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -2284.932% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 83.078% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -142.249% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | 78.371% |
| Kadimastem Ltd | 2.41 Million USD | 82.761% |
| Helix BioMedix, Inc. | 1.97 Million USD | 78.931% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 96.177% |
| BioStem Technologies, Inc. | 22.97 Million USD | 98.192% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -128.933% |
| LadRx Corporation | 3.81 Million USD | 89.1% |
| Cell Source, Inc. | 4.32 Million USD | 90.394% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 55.011% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 55.011% |
| NovAccess Global Inc. | 2.46 Million USD | 83.157% |
| Affymax, Inc. | 39.38 Million USD | 98.945% |
| Itoco Inc. | 919.14 Thousand USD | 54.797% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 90.197% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | 62.871% |
| Mobile Lads Corp. | 554.54 Thousand USD | 25.078% |
| CytoDyn Inc. | 18.05 Million USD | 97.699% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -1550.757% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -88.787% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | 70.737% |
| SYBLEU INC | 160.87 Thousand USD | -158.26% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | 77.125% |
| International Stem Cell Corporation | 5.27 Million USD | 92.118% |
| Bioxytran, Inc. | 3.82 Million USD | 89.124% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -689.254% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -1942.368% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 98.854% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | 74.321% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | 43.536% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 86.645% |
| Neutra Corp. | 243.82 Thousand USD | -70.403% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 97.62% |
| PureTech Health plc | 144.59 Million USD | 99.713% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 97.972% |
| IXICO plc | 4.7 Million USD | 91.173% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 95.277% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 99.647% |
| CSL Limited | 3.89 Billion USD | 99.989% |
| Cellectis S.A. | 97.32 Million USD | 99.573% |